Latest Commercialisation News

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Energy World Corporation Ltd plans to convert $440.5 million of debt into shares at a significant premium, reshaping its capital structure and boosting major shareholders’ stakes. Concurrently, the company announces key leadership changes to steer its next growth phase.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

ClearVue Technologies has secured $746,574 through a mix of equity and debt to support its international commercialisation efforts amid shifting market conditions.

3D Energi Limited has updated its prospective gas resource estimates in the Otway Basin, revealing a substantial 9.2 trillion cubic feet (Tcf) of gross recoverable gas across 51 prospects. The company is gearing up for a multi-well drilling campaign in 2025 targeting near-term commercialisation opportunities to bolster East Coast energy security.

Alligator Energy has completed a $17.25 million placement to fund critical development and exploration activities at its Samphire Uranium Project in South Australia, setting the stage for key milestones through 2026.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.